Bryant England on advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease

Dr Bryant England discusses the use of TNF-inhibitor versus non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD, and the effects on survival and respiratory hospitalisation outcomes. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00265-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://insta...